Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

Michelle is a lead editor at Forbes Advisor. She has been a journalist for over 35 years, writing about insurance for consumers for the last decade. Prior to covering insurance, Michelle was a ...

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

People who trust pharma are more interested in using the industry’s services – making building confidence in the sector key to realising the potential of patient centricity.

American drug major AbbVie Healthcare’s Indian arm, which is under the scanner for sponsoring foreign trips of 30 doctors in violation of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP ...

ABBV-932 is under clinical development by AbbVie and currently in Phase I for Schizophrenia ... dopamine receptor modulator and is administered through oral route in the form of capsule. GlobalData, ...

The department of pharmaceuticals (DoP) reprimanded AbbVie Healthcare India for unethical marketing practices involving over ₹1 crore spent on foreign vacations for 30 doctors under the guise of ...

The “Economic Loss Assistance Program” earmarks $10 billion in direct payments for farmers. While USDA will make the final calculations, Farm CPA Paul Neiffer estimates per acre producer ...

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to ...

AbbVie has a solid medium-term growth plan and the means to accomplish it. Acquisitions and licensing deals could make for unexpected upsides. Still, its shares aren't priced inexpensively at the ...

A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database ...

Meanwhile, Accredo was the exclusive pharmacy for most patients in SaveOnSP’s program, the Wall Street Journal reported. “Patient assistance is for patients, not middlemen,” J&J said in a ...